Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s expected to curtail widespread access to cheaper copies of the popular ...

(Bloomberg) -- Novo Nordisk A/S is ... sufficient for the country’s needs “to a large degree,” CEO Lars Fruergaard Jorgensen said Wednesday in a Bloomberg TV interview.

(Reuters) - The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, a declaration that ...